Raymond Lee, MD
Transplant Hepatology · la Jolla, CANPI 1356754360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,329, 5.8 times the $230 reported in 2019. That places this record below the midpoint for transplant hepatology clinicians in CA, where the typical reported total is $2,997.
Across 97 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$450
- Takeda Pharmaceuticals U.S.A., Inc.$273
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$263
- Intercept Pharmaceuticals, Inc.$239
- Johnson & Johnson$183
- Gilead$182
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,64894%
- Education$1626%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 4 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $263 |
| Intercept Pharmaceuticals, Inc. | 11 | $239 |
| Johnson & Johnson | 10 | $183 |
| Gilead | 3 | $182 |
| Novo Nordisk | 6 | $171 |
| Regeneron Healthcare Solutions, Inc. | 6 | $163 |
| Ipsen Biopharmaceuticals, Inc | 7 | $146 |
| AbbVie | 6 | $108 |
| Madrigal Pharmaceuticals | 4 | $79 |
| Eisai Inc. | 3 | $66 |
| Covidien LP | 1 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $64 |
| Merck | 3 | $58 |
| Sanofi | 2 | $57 |
| Genentech USA, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Veloxis Pharmaceuticals, Inc. | 1 | $24 |
| Evoke Pharma, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| Exelixis Inc. | 1 | $22 |
| Vivus LLC | 1 | $22 |
| Orphalan Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Eurofins Viracor, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$116
How this compares
$2,810 in reported general payments places this provider in the 45th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 22 | $77,352 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 31 | $1,970 |
| Lactulose | 17 | $617 |
| Spironolactone | 12 | $333 |
| Carvedilol | 25 | $177 |
| Ciprofloxacin Hcl | 13 | $146 |
| Furosemide | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $263 | $77,35222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 39 transplant hepatology providers in California.
Other transplant hepatology in la Jolla
- Julio GutierrezLos Angeles$895K
- Pei Lim LeeLos Angeles$79K
- Jennifer LaiSan Francisco$70K
- Kidist YimamSan Francisco$53K
- Beshoy YannyLos Angeles$50K
- Kali ZhouLos Angeles$50K
- Mindie NguyenStanford$50K
- Jasleen SinghLos Angeles$46K
- Bilal HameedSan Francisco$44K
- Brian LeeSan Bernardino$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.